LB PHARMACEUTICALS INC
LBRX
Analytical Summary
LB PHARMACEUTICALS INC shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
10-Year Financial Trajectory
QuarterlyHealth Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-K ↗ | Q3 FY2025 Sep 30, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q3 FY2024 Sep 30, 2024 10-Q ↗ | Q2 FY2024 Jun 30, 2024 10-Q ↗ | Q1 FY2024 Mar 31, 2024 10-Q ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Growth YoY (%) |
95.5%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
N/M |
98.5%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — | — | — | — | — |
| Net Income Growth YoY (%) |
-259.1%
Weak
↓
Weak
Declining
Year-over-year change in net income |
-126.2%
Weak
Weak
Year-over-year change in net income |
67.3%
Excellent
Excellent
Year-over-year change in net income |
— | — | — | — | — | — | — |
| FCF Growth YoY (%) |
96.4%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — | — | — | — | — | — | — | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-K ↗ | Q3 FY2025 Sep 30, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q3 FY2024 Sep 30, 2024 10-Q ↗ | Q2 FY2024 Jun 30, 2024 10-Q ↗ | Q1 FY2024 Mar 31, 2024 10-Q ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
0.0%
Excellent
↑
Excellent
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.0%
Excellent
→
Excellent
Stable
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
↑
Excellent
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
0.0%
Excellent
↑
Excellent
Improving
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — | — |
| FCF / Net Income (x) |
1.22x
Good
Good
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.58x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — |
1.54x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.16x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — | — | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-K ↗ | Q3 FY2025 Sep 30, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q3 FY2024 Sep 30, 2024 10-Q ↗ | Q2 FY2024 Jun 30, 2024 10-Q ↗ | Q1 FY2024 Mar 31, 2024 10-Q ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Common Equity (%) (%) |
-5.0%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-134%)
|
-3.8%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-125%)
|
-1.7%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-111%)
|
— |
5.3%
Caution
↓
Caution
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-64%)
|
5.4%
Caution
Caution
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-64%)
|
17.7%
Good
Good
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+18%)
|
— | — | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-K ↗ | Q3 FY2025 Sep 30, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q3 FY2024 Sep 30, 2024 10-Q ↗ | Q2 FY2024 Jun 30, 2024 10-Q ↗ | Q1 FY2024 Mar 31, 2024 10-Q ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt (USD) | $-320.68M | $-250.17M | $-269.74M | — | — | $-22.98M | — | — | — | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-K ↗ | Q3 FY2025 Sep 30, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q3 FY2024 Sep 30, 2024 10-Q ↗ | Q2 FY2024 Jun 30, 2024 10-Q ↗ | Q1 FY2024 Mar 31, 2024 10-Q ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $378.17M | $300.99M | $309.75M | — | — | $20.77M | — | — | — | — |
| Total Equity (USD) | $378.69M | $301.31M | $310.22M | $-103.87M | $-99.34M | $-94.55M | $-91.45M | $-77.44M | $-50.45M | $-34.47M |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-K ↗ | Q3 FY2025 Sep 30, 2025 10-Q ↗ | Q2 FY2025 Jun 30, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q3 FY2024 Sep 30, 2024 10-Q ↗ | Q2 FY2024 Jun 30, 2024 10-Q ↗ | Q1 FY2024 Mar 31, 2024 10-Q ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation Expense (USD) | $82.00K | — | — | — | $79.00K | — | — | — | — | — |
| Net Income, GAAP (USD) | $-19.05M | $-11.47M | $-5.31M | — | $-5.31M | $-5.07M | $-16.22M | — | — | — |
| Operating Cash Flow (USD) | $-23.29M | $-18.10M | — | — | $-8.13M | $-5.67M | — | — | — | — |
Secondary lens
Benchmark Lens
Compare LBRX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare LBRX against peers after checking the statement evidence.
Percentile Rankings
How LBRX compares to all companies
Peer Comparison
LBRX vs similar peers
Compare LBRX with peers
Stack LBRX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 3 years · 10 quarters